Antiviral therapies in children: has their time arrived?
The increase in the number and classes of antiviral agents that has occurred since the 1980s is remarkable. The rapid expansion in therapeutic options for previously untreatable illnesses challenges clinicians to gain familiarity and experience with these new drugs, especially with regard to their use in children. This article describes the clinical utilities, pharmacokinetics, and adverse effects of these new drugs to empower practitioners to use them appropriately.
Kimberlin
David W
DW
Department of Pediatrics, Division of Pediatric Infectious Diseases, The University of Alabama, Birmingham, AL 35233, USA. dkimberlin@peds.uab.edu
D019380:Anti-HIV Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000600:supply & distribution / Q000627:therapeutic use*; D001682:Biological Availability; D002648:Child; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D006525:Hepatitis, Viral, Human / Q000188:drug therapy / Q000821:virology; D006566:Herpesviridae Infections / Q000188:drug therapy / Q000821:virology; D006801:Humans; D030361:Papillomavirus Infections / Q000188:drug therapy / Q000821:virology; D010372:Pediatrics / Q000379:methods* / Q000639:trends; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000821:virology; D012449:Safety; D016896:Treatment Outcome; D014773:Virology / Q000379:methods / Q000639:trends; D014777:Virus Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology
D019380:Anti-HIV Agents; D000998:Antiviral Agents